The determinants of clinical outcome and clinical response to CRT are not the same

Heart Failure Reviews

Volumn 17, Issue 6, 2012, Pages 755-766

  Cleland, John G F ^a   Ghio, Stefano ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Cardiac resynchronization therapy; Heart failure; Outcome; Response

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONGESTIVE CARDIOMYOPATHY; DISABILITY; EVENT FREE SURVIVAL; HEART FAILURE; HEART LEFT VENTRICLE ASYNERGY; HEART LEFT VENTRICLE DYSSYNCHRONY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERVENTION STUDY; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT RESPONSE;

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; PATIENT SELECTION; PROGNOSIS; TREATMENT OUTCOME;

EID: 84868209235     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9268-9     Document Type: Article

References (60)

1. Cleland JG, Tavazzi L, Daubert J-C, Tageldien A, Freemantle N (2009) Cardiac resynchronization therapy. Are modern myths preventing appropriate use? J Am Coll Cardiol 53(7):608-611
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, Van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Bohm M, Corra U, della BP, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL, Zannad F (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESICM). Eur J Heart Fail 10(10):933-989
3. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, Van Veldhuisen DJ (2010) 2010 focused update of ESC guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the heart failure association and the European heart rhythm association. Eur J Heart Fail 12(11):1143-1153
4. Cleland JGF, Charlesworth A, Lubsen J, Swedberg K, Remme W, Erhardt L, Di Lenarda A, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson PA (2006) A comparison of the effects of carvedilol and metroprolol on 'well-being', morbidity and mortality (the Patient Journey) in patients with heart failure: A report from the carvedilol or metoprolol European trial (COMET). J Am Coll Cardiol 47(8):1603-1611
5. Cleland JGF (2002) How to assess new treatments for the management of heart failure: Composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 4(3):243-247
6. Cleland JGF, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, Hobbs FDR, Korewicki J, Madeira HC, Preda I, Swedberg K., van Gilst W, Widimsky J (2002) For the IMPROVEMENT of heart failure programme committees and investigators and the study group on diagnosis of the working group on heart failure of the European society of cardiology. An international survey of the management of heart failure in primary care. The IMPROVEMENT of heart failure programme. Lancet 360:1631-1639
7. Cleland JGF, Atkin SL (2007) Thiazolidinediones, deadly sins, surrogates and elephants. Lancet 370(9593):1103-1104
8. Freemantle N, Calvert M (2007) Composite and surrogate outcomes in randomised controlled trials. BMJ 334(7597):756-757
9. Anand IS, Florea VG, Fisher LD (2002) Surrogate end points in heart failure. J Am Coll Cardiol 39:1414-1421
10. Cleland JG, Tageldien A, Buga L, Wong K, Gorcsan J (2010) Should we be trying to define responders to cardiac resynchronization therapy? JACC Cardiovasc Imag 3(5):541-549
11. Cleland JGF, Nasir M, Tageldien A (2007) Cardiac resynchronization therapy or atriobiventricular pacing -what should it be called? Nat Clin Pract Cardiovasc Med 4(2):90-101
12. Cleland JGF, Tageldien A, Khaleva O, Hobson N, Clark AL (2007) Should patients who have persistent severe symptoms receive a left ventricular assist device or cardiac resynchronization therapy as the next step? Heart Fail Clin 3:267-273
13. Cleland JG, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijianowski M, Verboven Y, Tavazzi L (2008) Predicting the long-Term effects of cardiac resynchronisation therapy on mortality from baseline variables and the early response: A report from CARE-HF (cardiac resynchronisation in heart failure). J Am Coll Cardiol 52:438-445
14. Cleland JGF, Buga L (2010) Defibrillators -A shocking therapy for cardiomyopathy? Nat Rev Cardiol 7(2):69-70
15. Cleland JG, Buga L, Ghosh J, Nasir M (2010) Applying evidence-based device care in cardiovascular patients: which patient with heart failure and what device? JRCPL 40:229-239
16. Wikstrom BG, Lundqvist CB, Andren B, Lonnerholm S, Blomstrom P, Freemantle N, Remp T, Cleland JG (2009) The effects of aetiology on outcome in patients treated with cardiac resynchronisation therapy in the CARE-HF trial. Eur Heart J 30(7):782-788
17. Faggiano P et al (2001) Mechanisms and immediate outcome of in-hospital cardiac arrest in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 87:655-657
18. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J (1989) Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 80:1675-1680
19. Cleland JGF, Coletta AP, Yassin A, Hado H, Cullington D, Tageldien A, Clark AL (2008) Clinical trials update from the American college of cardiology 2008: CARISMA, TRENDS, meta-Analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE. Eur J Heart Fail 10(6):614-620
20. Chattopadhyay S, Alamgir F, Nikitin NP, Fraser AG, Clark AL, Cleland JG (2008) The effect of pharmacological stress on intraventricular dyssynchrony in left ventricular systolic dysfunction. Eur J Heart Failure 10(4):412-420
21. Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M, Shankar A, Cleland JGF, Tavazzi L (2009) Long term left ventricular reverse remodelling with cardiac resynchronization therapy. Results from the CARE-HF trial. Eur J Heart Failure 11(5):480-488
22. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ (1995) Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-Adrenergic blockade. J Am Coll Cardiol 25(5):1154-1161
23. Clark AL, Goode K, Cleland JGF (2008) The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. Eur J Heart Fail 10(7):696-702
24. Cleland JGF, Coletta A, Freemantle N, Velavan P, Tin L, Clark AL (2005) Clinical trials update from the American college of cardiology meeting: CARE-HF and the remission of heart failure, women's health study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Failure 7(5):931-936
25. Daubert J-C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Torok T, Linde C (2009) On behalf of the REVERSE study group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J Am Coll Cardiol 54:1837-1846
26. Cleland JG et al. (2011) Long-Term mortality with cardiac resynchronization therapy in heart failure. CARE-HF trial longterm follow-up. Eur J Heart Failure
27. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L (2006) On behalf of the CARE-HF study investigators. Longer-Term effects of cardiac resynchronization therapy on mortality in heart failure the cardiac resynchronization -heart failure (CARE-HF) trial extension phase. Eur Heart J 27(16):1928-1932
28. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL (2010) Cardiac-resynchronization therapy for mild-To-moderate heart failure. N Engl J Med 363(25): 2385-2395
29. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Courtney DM, Hasa J, Spinar J, Masip J, Peacock WF, Sliwa K, Gayat E, Filippatos G, Cleland JGF, Gheorghiade M (2010) The impact of early standard therapy on dyspnoea in patients with acute heart failure: The URGENT-dyspnoea study. Eur Heart J (in press, Epub ahead of print)
30. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of cardiology foundation/American heart association task force on practice guidelines: Developed in collaboration with the international society for heart and lung transplantation. Circulation 119(14): 1977-2016
31. Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, Fyfe DA, Leon AR, Oshinski JN (2010) Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 121(18):1985-1991
32. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J III, St John SM, De SJ, Murillo J (2008) Results of the predictors of response to CRT (PROSPECT) trial. Circulation 117(20):2608-2616
33. van Bommel RJ, Bax JJ, Abraham WT, Chung ES, Pires LA, Tavazzi L, Zimetbaum PJ, Gerritse B, Kristiansen N, Ghio S (2009) Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: A PROSPECT (Predictors of Response to CRT) sub-Analysis. Eur Heart J 30(20):2470-2477
34. St John SM, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, Abraham WT, Gold MR, Hassager C, Herre JM, Linde C (2009) Cardiac resynchronization induces major structural and functional reverse remodelling in patients with New York heart association class I/II heart failure. Circulation 120(19):1858-1865
35. Linde C, Abraham WT, Gold MR, St.John Sutton M, Ghio S, Daubert J-C (2008) On behalf of the REVERSE (resynchronization reverses remodelling in systolic left ventricular dysfunction) study. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 52:1834-1843
36. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L (2005) For the cardiac resynchronisation -heart failure (CARE-HF) study investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 352(15):1539-1549
37. Cleland JGF, Freemantle N, Daubert J-C, Toff W, Leisch F, Tavazzi L (2008) Long-Term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: A report from the CARE-HF study. Heart 94(3):278-283
38. Cleland JG, Freemantle N, Calvert M (2009) Effects of cardiac resynchronisation therapy on long-Term quality of life. An analysis from the CARE-HF study. Am Heart J 157(3):457-466
39. Ypenburg C, van Bommel RJ, Borleffs CJ, Bleeker GB, Boersma E, Schalij MJ, Bax JJ (2009) Long-Term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodelling at midterm follow-up. J Am Coll Cardiol 53(6):483-490
40. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Messenger J (2002) For the MIRACLE study group. Cardiac resynchronisation in chronic heart failure. N Engl J Med 346(24): 1845-1853
41. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Demets D, White BG, DeVries DW, Feldman AM (2004) For the comparison of medical therapy padihfCi. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New Engl J Med 350:2140-2150
42. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K (2003) Combined cardiac resynchronization and implantable cardio version defibrillation in advanced chronic heart failure: The MIRACLE ICD trial. JAMA 289:2685-2694
43. Beshai JF et al (2007) Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. New Engl J Med 357: 2461-2471
44. Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361(14):1329-1338
45. Wilkoff B, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A (2002) Dual chamber and VVI implantable defibrillator trial investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The dual chamber and VVI implantable defibrillator (DAVID) trial. JAMA 288(24):3115-3123
46. Auricchio A, Metra M, Gasparini M, Lamp B, Klersy C, Curnis A, Fantoni C, Gronda E, Vogt J (2007) Long-Term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol 99(2):232-238
47. Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B, Curnis A, Vogt J, Klersy C (2008) Long-Term survival in patients undergoing cardiac resynchronization therapy: The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 29(13): 1644-1652
48. Di BL, Gasparini M, Lunati M, Santini M, Landolina M, Boriani G, Curnis A, Bocchiardo M, Vincenti A, Denaro A, Valsecchi S, Natale A, Padeletti L (2008) Antiarrhythmic effect of reverse ventricular remodelling induced by cardiac resynchronization therapy: The InSync ICD (Implantable Cardioverter- Defibrillator) Italian registry. J Am Coll Cardiol 52(18):1442-1449
49. Richardson M, Freemantle N, Calvert MJ, Cleland JGF, Tavazzi L (2007) Predictors and treatment response with cardiac resynchronisation therapy in patients with heart failure characterised by dyssynchrony: A predefined analysis from the CARE-HF trial. Eur Heart J 28(15):1827-1834
50. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D, Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ (2011) Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation 123(10):1061-1072
51. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS (2011) Cardiac resynchronization therapy is more effective in women than in men: The MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) trial. J Am Coll Cardiol 57(7):813-820
52. Barsheshet A, Goldenberg I, Moss AJ, Eldar M, Huang DT, McNitt S, Klein HU, Hall WJ, Brown MW, Goldberger JJ, Goldstein RE, Schuger C, Zareba W, Daubert JP (2010) Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J
53. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, Hall WJ, Pfeffer MA, Moss AJ (2010) Effect of cardiac resynchronization therapy on reverse remodelling and relation to outcome: multicenter automatic defibrillator implantation trial: Cardiac resynchronization therapy. Circulation 122(10):985-992
54. Cleland JG, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L (2005) CARE-HF study steering committee and investigators. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 7(2):205-214
55. Moss AJ et al (2005) Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADITCRT): Design and clinical protocol. Ann Noninvasive Electrocardiol 10:34-43
56. Barsheshet A, Goldenberg I, Narins CR, Moss AJ, McNitt S, Wang PJ, Huang DT, Hall WJ, Zareba W, Eldar M, Guetta V (2010) Time dependence of life-Threatening ventricular tachyarrhythmias after coronary revascularization in MADIT-CRT. Heart Rhythm 7(10):1421-1427
57. Dhingra R, Ho NB, Benjamin EJ, Wang TJ, Larson MG, D'Agostino RB Sr, Levy D, Vasan RS (2005) Cross-sectional relations of electrocardiographic QRS duration to left ventricular dimensions: The Framingham heart study. J Am Coll Cardiol 45(5):685-689
58. Pilhall M, Riha M, Jern S (1992) Exercise-induced QRS changes in healthy men and women: A multivariate analysis on their relation to background data and exercise performance. Eur Heart J 13(10):1316-1324
59. Egoavil CA, Ho RT, Greenspon AJ, Pavri BB (2005) Cardiac resynchronization therapy in patients with right bundle branch block: Analysis of pooled data from the MIRACLE and Contak CD trials. Heart Rhythm 2:611-615
60. Gervais R, Leclerc C, Shankar A, Jacobs S, Eiskjaer H, Johannessen A, Freemantle N, Cleland JGF, Tavazzi L, Daubert J-C (2009) On behalf of the CARE-HF investigators. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: A sub-Analysis of the CARE-HF trial. Eur J Heart Fail 11(7):699-705